ClinicalTrials.gg
RecruitingNCT07659795TARGET-D 203Updated Nov 12, 2026

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

A Phase 2 interventional study of VS-7375 and cetuximab in Colorectal Cancer, sponsored by Verastem, Inc.. Recruiting at 30 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Verastem, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Oct 26, 2026Study contact changed13 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 187 studies testing cetuximab in Colorectal Neoplasms — 35 open to participants now, 43 under way, 7 of them phase 3. Cetuximab · Colorectal Neoplasms.

Planned enrollment
46th of 185
150 · median 60
Started
2026
with 7 others
Phase 2
107 of 187
20 open now
Primary completion
2027-06
later than 22 of 42 live
Registered
184th of 187
by date

Among the 187 studies testing cetuximab in Colorectal Neoplasms, this one is the 46th largest by planned enrollment of the 185 interventional ones that give a count, is one of 8 that started in 2026, is one of 107 in phase 2, reaches primary completion later than 22 of the 42 other live ones, and was the 184th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

35 of the 187 studies testing cetuximab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

29 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies testing cetuximab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histopathology confirmed CRC
  • per 1.1
  • Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)
  • PS=0 or 1

    2L+ patients:

  • Must have received at least 1 standard chemotherapy for metastatic colorectal adenocarcinoma
  • Have documented disease progression during or following their most recent
  • Have either stable disease, partial response (PR), or complete response (CR) by RECIST v1.1 as the best overall response (BOR) during at least 1 prior systemic therapy.

    1L patients:

  • Treatment-naïve or received no more than 1 cycle of standard systemic therapy for metastatic disease.

Exclusion criteria

Exclusion Criteria:

  • Have any other documented co-existing common RAS mutation(s)
  • Prior anti-cancer Tx within 4 weeks or drug-specific timeline within first treatment dose, whichever shorter
  • Major surgery within 4 weeks of first treatment dose
  • Radiation therapy (RT) within 1 week of first treatment dose
  • Receipt of prior direct RAS inhibitor
  • Receipt of more than 1 therapy
  • Untreated or symptomatic
  • Receipt of strong inhibitor/inducer or CYP3A4 sensitive substrates with narrow therapeutic index within 14 days or drug-specific timeline within first treatment dose, whichever is shorter
  • Receipt of PPI or H2 blocker within 5 days
  • Inability to swallow oral medication
  • Other protocol-defined inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    VS-7375 Monotherapy or Preferred Combination in 2L+ CRC

    Participants randomized to a treatment in 2:1 ratio

    Drug: VS-7375 · Drug: cetuximab · Drug: panitumumab

  • Experimental
    VS-7375 with chosen regimen in 2L+ CRC

    Drug: VS-7375 · Drug: cetuximab · Drug: panitumumab

  • Experimental
    VS-7375 + cetuximab and mFOLFOX in 1L CRC

    Drug: Cetuximab + mFOLFOX6

Interventions

06

What researchers measure

Primary outcomes

  1. Confirmed ORR by blinded independent central review (BICR) per RESIST v1.1 - 2L CRC only

    Overall Response Rate per RECIST version 1.1, per blinded independent central review (BICR)

    Time frame: 6 months

  2. To characterize the safety and tolerability of VS-7375 monotherapy or in combination with cetuximab or panitumumab, administered on a daily oral schedule in participants with KRAS G12D-mutated 2L+ CRC

    Proportion/number of participants with AEs, TEAEs, TRAEs, SAEs, and dose interruptions/reductions and discontinuations

    Time frame: 6 months

  3. To characterize the safety and tolerability of VS-7375 in combination with cetuximab + mFOLFOX, administered on a daily oral schedule in participants with KRAS G12D-mutated 1L CRC

    Proportion/number of participants with AEs, TEAEs, TRAEs, SAEs, and dose interruptions/reductions and discontinuations

    Time frame: 6 months

Secondary outcomes

  1. Confirmed ORR per RECIST v1.1 assessed by BICR (primary) and Investigator (secondary) assessments

    To evaluate additional efficacy parameters of VS-7375 monotherapy and VS-7375 in combination with cetuximab or panitumumab or cetuximab + mFOLFOX, administered on a daily oral schedule in participants with KRAS G12D-mutated CRC

    Time frame: 24 months

  2. Plasma Pharmacokinetics (PK) of VS-7375 and relevant metabolites, Cmax

    Maximum concentration (Cmax)

    Time frame: 20 weeks

  3. Plasma Pharmacokinetics (PK) of VS-7375 and relevant metabolites, AUC

    Area under plasma Concentration (AUC) 0 to t

    Time frame: 20 weeks

  4. To evaluate Pharmacodynamics (PD) and other relevant blood tumor markers specific to tumor type

    CA19-9, CEA, CA-125

    Time frame: Up to 2.5 years

  5. To assess the health-related quality of life and disease based on European Organization for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire Core module C30 (QLQ-C30)

    The EORTC QLQ-C30 is a validated questionnaire to assess the quality of life of colorectal cancer patients

    Time frame: 24 months

  6. Time to next therapy

    To assess the interval between initiation of study treatment and initiation of subsequent treatment

    Time frame: 24 months

Other outcomes

  1. Imaging of tumor metabolism changes in 2L monotherapy patients

    To assess tumor metabolism dynamics on FDG-PET/CT

    Time frame: 24 months

07

Study locations

30 of 30 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

9 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jun 2027, 11 months after the start.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's planned 11 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2026
First posted
Jun 22, 2026
StartActual
Jul 28, 2026
Primary completionEst.
Jun 2027
CompletionEst.
Dec 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
13 sites added
Show 13 added (9 United States, 4 Australia)
  • Perlmutter Cancer Center at NYU Langone Health (contact for more locations) · New York, United States
  • Calvary Mater Newcastle · Waratah, Australia
  • BRCR - Tamarac · Tamarac, United States
  • University of Wisconsin · Madison, United States
  • University of North Carolina · Chapel Hill, United States
  • Case Western, University Hospitals Cleveland Medical Center · Cleveland, United States
  • Icon Cancer Centre Townsville · Hyde Park, Australia
  • Icon Cancer Centre Hobart · Hobart, Australia
  • HonorHealth · Scottsdale, United States
  • Cedars-Sinai Medical Center · Los Angeles, United States
  • Huntsman Cancer Institute - University of Utah · Salt Lake City, United States
  • Alfred Hospital · Melbourne, Australia
  • BRCR - Coral Springs · Coral Springs, United States
across 8 updates, Sep 25, 2026 – Oct 26, 2026
Contact
Study contact changed: V•••@verastem.com→V•••@verastem.com. See the current contact
Oct 5, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Icon Cancer Centre South Brisbane · South Brisbane, AustraliaContact a•••@icon.team · •••4700→A•••@icon.team · •••4700
  • Icon Cancer Centre Adelaide · Kurralta Park, AustraliaContact a•••@icon.team→E•••@icon.team
  • Calvary Mater Newcastle · Waratah, AustraliaContact e•••@health.nsw.gov.au · •••3290→K•••@health.nsw.gov.au · •••3290
across 2 updates, Oct 15, 2026 – Nov 12, 2026
Show all 9 updates
  1. Nov 12, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Calvary Mater Newcastle · Waratah, AustraliaContact e•••@health.nsw.gov.au · •••3290→K•••@health.nsw.gov.au · •••3290
  2. Oct 26, 2026
    1 site added
    Show site
    • BRCR - Coral Springs · Coral Springs, United States
  3. Oct 21, 2026
    4 sites added
    Show 4 added (3 United States, 1 Australia)
    • HonorHealth · Scottsdale, United States
    • Cedars-Sinai Medical Center · Los Angeles, United States
    • Huntsman Cancer Institute - University of Utah · Salt Lake City, United States
    • Alfred Hospital · Melbourne, Australia
  4. Oct 15, 2026
    2 sites added
    Show 2 added (2 Australia)
    • Icon Cancer Centre Townsville · Hyde Park, Australia
    • Icon Cancer Centre Hobart · Hobart, Australia
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Icon Cancer Centre South Brisbane · South Brisbane, AustraliaContact a•••@icon.team · •••4700→A•••@icon.team · •••4700
    • Icon Cancer Centre Adelaide · Kurralta Park, AustraliaContact a•••@icon.team→E•••@icon.team
  5. Oct 9, 2026
    1 site added
    Show site
    • Case Western, University Hospitals Cleveland Medical Center · Cleveland, United States
  6. Oct 6, 2026
    1 site added
    Show site
    • University of North Carolina · Chapel Hill, United States
  7. Oct 5, 2026
    2 sites added
    Show 2 added (2 United States)
    • BRCR - Tamarac · Tamarac, United States
    • University of Wisconsin · Madison, United States
    Contact Study contact changed: V•••@verastem.com→V•••@verastem.com. See the current contact
  8. Sep 29, 2026
    1 site added
    Show site
    • Calvary Mater Newcastle · Waratah, Australia
  9. Sep 25, 2026
    1 site added
    Show site
    • Perlmutter Cancer Center at NYU Langone Health (contact for more locations) · New York, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07659795
Lead sponsor
Verastem, Inc.
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
Jul 28, 2026
Primary completion
Jun 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Verastem Call Center
Contact
VS-7375-203TrialSupport@verastem.com
7812924204
Bina Tejura, MD
Contact
VS-7375-203Medical@verastem.com

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: KRAS G12D Inhibitor VS-7375 · Cetuximab

Start the discussion